Results 241 to 250 of about 206,699 (375)

Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine. [PDF]

open access: yesBrain
Kopruszinski CM   +15 more
europepmc   +1 more source

Combined Tumor Infiltrating Lymphocytes and PD‐L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

open access: yesHead &Neck, EarlyView.
ABSTRACT Objectives To determine if the assessment of CD8+ tumor‐infiltrating lymphocytes (TILs) adds prognostic information to the PD‐L1 combined positive score (CPS) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Methods A retrospective case series was performed of 77 patients with R/M HNSCC between 2003 and 2019.
Catherine T. Haring   +8 more
wiley   +1 more source

Ultra‐Hypofractionated Radiotherapy for Early‐Stage Glottic Cancer: Real‐World Data From a Single Center

open access: yesHead &Neck, EarlyView.
ABSTRACT Background In recent years, smaller‐volume radiotherapy has attracted attention. It appears to be a safe and effective treatment for glottic laryngeal cancer. This study evaluated the results of ultra‐hypofractionated radiotherapy for early glottic laryngeal cancer in unfit patients.
Mete Gundog, Esin Kiraz
wiley   +1 more source

Drug Reaction with Eosinophilia and Systemic Symptoms Induced by Diosmin and Hesperidin: A Case Report

open access: yesClinical, Cosmetic and Investigational Dermatology
Pasita Palakornkitti, Teerapong Rattananukrom Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandCorrespondence: Teerapong Rattananukrom, Division of Dermatology, Department of ...
Palakornkitti P, Rattananukrom T
doaj  

Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP)

open access: bronze, 2004
Ralph V. Boccia   +10 more
openalex   +1 more source

Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy. [PDF]

open access: yesFront Immunol
Bao H   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy